StratumSkin science, cited
Ingredient Index

Acne

Clindamycin with BPO

Prescription combination

Overall grade ATypical strength 1% / 5%2 sources

An antibiotic paired with benzoyl peroxide, which is the point: the peroxide stops bacteria developing resistance to the antibiotic. Well evidenced as a combination. Topical antibiotics on their own are now discouraged for exactly that reason.

Claim by claim

BAcneWorks, and the peroxide is what stops resistance developing.
DClindamycin aloneTopical spironolactone beat clindamycin solution on comedones. Antibiotic monotherapy is now discouraged.

References

  1. Yuan Y, et al. Topical, light-based, and complementary interventions for acne: an overview of systematic reviews. Cochrane Database of Systematic Reviews, 2024.ACochrane overview of systematic reviews·Much of the head-to-head evidence between topical acne treatments is rated low or very low certainty. The honest position on most comparisons is that nobody knows.DOI 10.1002/14651858.CD014918.pub2
  2. Basendwh MA, Alharbi AA, Bukhamsin SA, et al. The efficacy of topical clascoterone versus systemic spironolactone for treatment of acne vulgaris: a systematic review and network meta-analysis. PLOS ONE, 2024.BNetwork meta-analysis, 7 studies, 2,006 patients·Spironolactone 200 mg produced a large reduction in total lesion count. Topical clascoterone beat placebo more modestly.DOI 10.1371/journal.pone.0298155

Your turn

Did this hold up? Tell us honestly — especially if it didn’t.

Anonymous. Stored in your browser.

The Sunday study

One paper a week, explained properly

We pick a single new study, tell you what it measured, how many people it measured it in, and whether it should change anything you're doing — plus the two articles we published that week. No panic, and no hype.

We don't recommend products yet. When we do, they'll be things you can actually buy in India, any affiliate link will be labelled as one, and a commission will never buy a recommendation.

One email each Sunday. Unsubscribe in one click.